[The pleiotropic drug resistance phenotype: role of reverting agents "in vitro" and "in vivo"]

Haematologica. 1991 Jun:76 Suppl 3:173-6.
[Article in Italian]
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Acute Disease
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carrier Proteins / antagonists & inhibitors*
  • Carrier Proteins / metabolism
  • Cefoperazone / pharmacology*
  • Child
  • Cyclosporine / pharmacology*
  • Doxorubicin / pharmacology
  • Drug Evaluation
  • Drug Synergism
  • Humans
  • Leukemia / drug therapy*
  • Leukemia / enzymology
  • Membrane Glycoproteins / antagonists & inhibitors*
  • Membrane Glycoproteins / metabolism
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / metabolism
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism
  • Nicardipine / pharmacology*
  • Nicardipine / therapeutic use
  • Phenotype
  • RNA, Messenger / analysis
  • RNA, Neoplasm / analysis
  • Verapamil / pharmacology*

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Carrier Proteins
  • Membrane Glycoproteins
  • Neoplasm Proteins
  • RNA, Messenger
  • RNA, Neoplasm
  • Cefoperazone
  • Doxorubicin
  • Cyclosporine
  • Verapamil
  • Nicardipine